Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EO 2463

Next Previous
Drug Profile

EO 2463

Alternative Names: EO-2463

Latest Information Update: 29 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enterome
  • Class Antineoplastics; Bacterial antigens; Cancer vaccines; Immunotherapies; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 23 Jun 2025 Efficacy data from the phase I/II SIDNEY trial in indolent non-Hodgkin's lymphoma released by the Enterome
  • 18 Jun 2025 9444545- Financial info in KDM. Regulatory update for EMA- KDM and HE. Planned phase III trial- KDM and HE
  • 13 Jun 2025 Enterome had a positive scientific advice meeting with EMA for EO 2463 in Non hodgkins lymphoma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top